Rumgay, H. et al. Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption: a population attributable fraction analysis. Lancet Oncol. 25, 1413–1423 (2024).
Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).
Abdulla, R. et al. Clinicopathological analysis of oral squamous cell carcinoma among the younger age group in coastal Karnataka, India: a retrospective study. J. Oral. Maxillofac. Pathol. 22, 180–187 (2018).
Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Prim. 6, 92 (2020).
Ekanayaka, R. P. & Tilakaratne, W. M. Impact of histopathological parameters in prognosis of oral squamous cell carcinoma. Oral. Dis. 31, 1420–1438 (2025).
Hoesseini, A. et al. Head and neck cancer patients’ preferences for individualized prognostic information: a focus group study. BMC Cancer 20, 399 (2020).
Hoesseini, A. et al. Prognostic model for overall survival of head and neck cancer patients in the palliative phase. BMC Palliat. Care. 23, 54 (2024).
Kim, J. & DeBerardinis, R. J. Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab. 30, 434–446 (2019).
Demicco, M., Liu, X. Z., Leithner, K. & Fendt, S. M. Metabolic heterogeneity in cancer. Nat. Metab. 6, 18–38 (2024).
Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27–47 (2016).
Warburg, O. On respiratory impairment in cancer cells. Science 124, 269–270 (1956).
Ohshima, K. & Morii, E. Metabolic reprogramming of cancer cells during tumor progression and metastasis. Metabolites 11, 28 (2021).
Nguyen, D. X. & Massague, J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 8, 341–352 (2007).
Evers, T. M. J. et al. Deciphering metabolic heterogeneity by single-cell analysis. Anal. Chem. 91, 13314–13323 (2019).
Gong, Y. et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 33, 51–64.e9 (2021).
Flint, L. E. et al. Characterization of an aggregated three-dimensional cell culture model by multimodal mass spectrometry imaging. Anal. Chem. 92, 12538–12547 (2020).
Xiao, Z., Dai, Z. & Locasale, J. W. Metabolic landscape of the tumor microenvironment at single cell resolution. Nat. Commun. 10, 3763 (2019).
DeBerardinis, R. J. & Chandel, N. S. Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200 (2016).
Jin, J., Byun, J. K., Choi, Y. K. & Park, K. G. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp. Mol. Med. 55, 706–715 (2023).
Miki, K. et al. Glutaminolysis is associated with mitochondrial pathway activation and can be therapeutically targeted in glioblastoma. Cancer Metab. 12, 35 (2024).
Lee, K. M. et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 26, 633–47.e7 (2017).
Zhang, L. et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci. Transl. Med. 11, eaau1167 (2019).
Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514, 628–632 (2014).
Hu, J. et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat. Biotechnol. 31, 522–529 (2013).
TeSlaa, T., Ralser, M., Fan, J. & Rabinowitz, J. D. The pentose phosphate pathway in health and disease. Nat. Metab. 5, 1275–1289 (2023).
Patra, K. C. & Hay, N. The pentose phosphate pathway and cancer. Trends Biochem. Sci. 39, 347–354 (2014).
Giacomini, I., Ragazzi, E., Pasut, G., & Montopoli M. The pentose phosphate pathway and its involvement in cisplatin resistance. Int. J. Mol. Sci. 21, 937 (2020).
Gong, Y. et al. SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway. Commun. Biol. 8, 36 (2025).
Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572–1573 (2010).
Tranby, E. P. et al. Oral cancer prevalence, mortality, and costs in medicaid and commercial insurance claims data. Cancer Epidemiol. Biomark. Prev. 31, 1849–1857 (2022).
Zhou, X. et al. Genomic alterations in oral multiple primary cancers. Int J. Oral. Sci. 16, 13 (2024).
Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 21, 297–308 (2012).
Weinberg, F. et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. 107, 8788–8793 (2010).
LeBleu, V. S. et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16, 992–1003 (2014). 1-15.
Yao, C. H. et al Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation. Elife. 8, e41351 (2019).
Davis, R. T. et al. Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing. Nat. Cell Biol. 22, 310–320 (2020).
Danko, B. et al. Metabolic pathway-based subtypes associate glycan biosynthesis and treatment response in head and neck cancer. NPJ Precis. Oncol. 8, 116 (2024).
Bansal, A. & Simon, M. C. Glutathione metabolism in cancer progression and treatment resistance. J. Cell Biol. 217, 2291–2298 (2018).
Harris, I. S. et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell. 27, 211–222 (2015).
Uslu, C., Kapan, E. & Lyakhovich, A. Cancer resistance and metastasis are maintained through oxidative phosphorylation. Cancer Lett. 587, 216705 (2024).
Li, S. S. et al. FAO-fueled OXPHOS and NRF2-mediated stress resilience in MICs drive lymph node metastasis. Proc. Natl. Acad. Sci. 122, e2411241122 (2025).
Xu, Y., Xue, D., Bankhead, A. 3rd & Neamati, N. Why all the fuss about oxidative phosphorylation (OXPHOS)?. J. Med Chem. 63, 14276–14307 (2020).
Beerkens, A. P. M. et al. Mitochondria targeting of oxidative phosphorylation inhibitors to alleviate hypoxia and enhance anticancer treatment efficacy. Clin. Cancer Res. 31, 1186–1193 (2025).
Greene, J., Segaran, A. & Lord, S. Targeting OXPHOS and the electron transport chain in cancer; molecular and therapeutic implications. Semin Cancer Biol. 86, 851–859 (2022).
Zhang, E. et al. Identification of subgroups along the glycolysis-cholesterol synthesis axis and the development of an associated prognostic risk model. Hum. Genom. 15, 53 (2021).
Jiang, M., Gu, X., Xu, Y. & Wang, J. Metabolism-associated molecular classification and prognosis signature of head and neck squamous cell carcinoma. Heliyon 10, e27587 (2024).
Li, L. et al. Cuproptosis/OXPHOS tendency prediction of prognosis and immune microenvironment of esophageal squamous cell carcinoma: bioinformatics analysis and experimental validation. Gene 902, 148156 (2024).
Galber, C., Acosta, M. J., Minervini, G. & Giorgio, V. The role of mitochondrial ATP synthase in cancer. Biol. Chem. 401, 1199–1214 (2020).
Wang, T., Ma, F. & Qian, H. L. Defueling the cancer: ATP synthase as an emerging target in cancer therapy. Mol. Ther. Oncolytics. 23, 82–95 (2021).
Cheng, Y. et al. Downregulation of ATP5F1D inhibits mtROS/NLRP3/caspase-1/GSDMD axis to suppress pyroptosis-mediated malignant progression of endometrial cancer. Int Immunopharmacol. 139, 112808 (2024).
Poliakov, E., Managadze, D. & Rogozin, I. B. Generalized portrait of cancer metabolic pathways inferred from a list of genes overexpressed in cancer. Genet. Res. Int. 2014, 646193 (2014).
Wang, Z. et al. High throughput proteomic and metabolic profiling identified target correction of metabolic abnormalities as a novel therapeutic approach in head and neck paraganglioma. Transl. Oncol. 14, 101146 (2021).
Yi, J., Gao, W., Wu, C., Yang, R. & Yu, C. A multidimensional pan-cancer analysis of NDUFA4L2 and verification of the oncogenic value in colon cancer. FASEB J. 39, e70300 (2025).
Shang, B. et al. ALDOC promotes non-small cell lung cancer through affecting MYC-mediated UBE2N transcription and regulating Wnt/beta-catenin pathway. Aging 15, 9614–9632 (2023).
Pes, G. M., Errigo, A., Soro, S., Longo, N. P. & Dore, M. P. Glucose-6-phosphate dehydrogenase deficiency reduces susceptibility to cancer of endodermal origin. Acta Oncol. 58, 1205–1211 (2019).
Lan, T. et al. Glucose-6-phosphate dehydrogenase maintains redox homeostasis and biosynthesis in LKB1-deficient KRAS-driven lung cancer. Nat. Commun. 15, 5857 (2024).
Kim, J. W. & Dang, C. V. Multifaceted roles of glycolytic enzymes. Trends Biochem. Sci. 30, 142–150 (2005).
de Padua, M. C. et al. Disrupting glucose-6-phosphate isomerase fully suppresses the “Warburg effect” and activates OXPHOS with minimal impact on tumor growth except in hypoxia. Oncotarget 8, 87623–87637 (2017).
Yang, H. D. et al. T-cell immune regulator 1 enhances metastasis in hepatocellular carcinoma. Exp. Mol. Med. 50, e420 (2018).
Gao, W. et al. The role of S-nitrosylation of PFKM in regulation of glycolysis in ovarian cancer cells. Cell Death Dis. 12, 408 (2021).
Shen, X. et al. PFKM promotes the progression of gastric cancer by up-regulating CNTN1 expression through H3K18la modification. Appl. Biochem. Biotechnol. 197, 5885–5901 (2025).
Cunningham, J. T., Moreno, M. V., Lodi, A., Ronen, S. M. & Ruggero, D. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell 157, 1088–1103 (2014).
Gao, F. et al. Identification of ubiquinol cytochrome c reductase hinge (UQCRH) as a potential diagnostic biomarker for lung adenocarcinoma. Open Biol. 6, 150256 (2016).
Bu, W., Cao, M., Wu, X. & Gao, Q. Prognosis prediction of head and neck squamous cell carcinoma through the basement membrane-related lncRNA risk model. Front Mol. Biosci. 11, 1421335 (2024).
Lai, J., Huang, R. & Huang, J. Predicting head and neck cancer response to radiotherapy with a chemokine-based model. Sci. Rep. 15, 28450 (2025).
Su, F. et al. Quantitative proteomics identified 3 oxidative phosphorylation genes with clinical prognostic significance in gastric cancer. J. Cell Mol. Med. 24, 10842–10854 (2020).
Chen, W., Yang, Z. & Chen, Y. A novel oxidative phosphorylation-associated gene signature for prognosis prediction in patients with hepatocellular carcinoma. Dis. Markers 2022, 3594901 (2022).
Zhan, Z., Lin, K. & Wang, T. Construction of oxidative phosphorylation-related prognostic risk score model in uveal melanoma. BMC Ophthalmol. 24, 204 (2024).
Lin, W. et al. A novel mitochondrial metabolism-related gene signature for predicting the prognosis of oesophageal squamous cell carcinoma. Aging 16, 9649–9679 (2024).
Liao, R. G. et al. A novel mitochondrial-related risk model for predicting prognosis and immune checkpoint blockade therapy response in uterine corpus endometrial carcinoma. Sci. Rep. 15, 1404 (2025).
Wu, C. S. et al. Integrated multi-omics analyses of oral squamous cell carcinoma reveal precision patient stratification and personalized treatment strategies. Cancer Lett. 614, 217482 (2025).
Huang, C. et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 39, 361–79.e16 (2021).
Zhou, Z. et al. Prognosis-related molecular subtyping in head and neck squamous cell carcinoma patients based on glycolytic/cholesterogenic gene data. Cancer Cell Int. 23, 37 (2023).
Kanehisa, M. Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).
Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. 102, 15545–15550 (2005).
Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).
Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–30.e14 (2018).
Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1–22 (2010).
Simon, N., Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for Cox’s proportional hazards model via coordinate descent. J. Stat. Softw. 39, 1–13 (2011).
Tay, J. K., Narasimhan, B. & Hastie, T. Elastic net regularization paths for all generalized linear models. J. Stat. Softw. 106, 1–31 (2023).
Tang, D. et al. SRplot: a free online platform for data visualization and graphing. PLoS One 18, e0294236 (2023).
Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 47, D442–D450 (2019).
